Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Relative Value
The Relative Value of one AUPH stock under the Base Case scenario is 17.68 USD. Compared to the current market price of 5.09 USD, Aurinia Pharmaceuticals Inc is Undervalued by 71%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
AUPH Competitors Multiples
Aurinia Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CA |
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
732.1m USD | 4.2 | -9.4 | -5.7 | -5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.8B USD | 5.3 | 59.6 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.6B USD | 5.2 | 21.8 | 16.3 | 24.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.8B USD | 10.3 | 28.1 | 22.4 | 23.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | ||
AU |
CSL Ltd
ASX:CSL
|
133.7B AUD | 6.2 | 35.5 | 21.5 | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.3B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.5B USD | 6.2 | -9 | -9.5 | -8.1 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.4B USD | 3.2 | 27.1 | 14.6 | 18.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |